Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis

American Journal of Gastroenterology

Volumn 111, Issue 9, 2016, Pages 1350-1357

  Amin, S ^a   Mhango, G ^a   Lin, J ^a   Aronson, A ^a   Wisnivesky, J ^a   Boffetta, P ^a   Lucas, Aimee L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC COMORBIDITY SEVERITY INDEX; DIABETIC PATIENT; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; SURVIVAL TIME; CANCER REGISTRY; DIABETES MELLITUS, TYPE 2; INFORMATION RETRIEVAL; MEDICARE; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PROPORTIONAL HAZARDS MODEL; PROTECTION; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFORMATION STORAGE AND RETRIEVAL; MALE; MEDICARE; METFORMIN; PANCREATIC NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UNITED STATES;

EID: 84978695254     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.288     Document Type: Article

References (43)

1. Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD; http://seer. cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER website, April 2013.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
3. Lee M-S, Hsu C-C, Wahlqvist ML et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
4. Noto H, Tsujimoto T, Sasazuki T et al. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011; 17: 616-28.
5. Adami HO, Chow WH, Nyrén O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996; 88: 1472-7.
6. Song S, Wang B, Zhang X et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. PLoS One 2015; 10: e0134321.
7. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-62.
8. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
9. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-37.
10. Noto H, Goto A, Tsujimoto T et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411.
11. Zhang Z-J, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 707-10.
12. Currie CJ, Poole CD, Jenkins-Jones S et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
13. Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18.
14. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006; 44: 921-8.
15. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
17. Klabunde CN, Potosky AL, Legler JM et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-67.
18. Rector TS, Wickstrom SL, Shah M et al. Specificity and sensitivity of claimsbased algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004; 39: 1839-57.
19. Hebert PL, Geiss LS, Tierney EF et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270-7.
20. Young BA, Lin E, Von Korff M et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008; 14: 15-23.
21. Joish VN, Malone DC, Wendel C et al. Development and validation of a diabetes mellitus severity index: a risk-adjustment tool for predicting health care resource use and costs. Pharmacother J Hum Pharmacol Drug Ther 2005; 25: 676-84.
22. Parmar AD, Vargas GM, Tamirisa NP et al. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery 2014; 156: 280-9.
23. Procedure Codes for SEER-Medicare Analyses [Internet]. [cited 21 August 2015]. Available from http://healthcaredelivery.cancer.gov/seermedicare/considerations/procedure-codes.html.
24. Lin JJ, Gallagher EJ, Sigel K et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med 2015; 191: 448-54.
25. Li D, Yeung SJ, Hassan MM et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-8.
26. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
27. Bodmer M, Becker C, Meier C et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012; 107: 620-6.
28. Singh S, Singh PP, Singh AG et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 510-9; quiz 520.
29. Sadeghi N, Abbruzzese JL, Yeung S-CJ et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18: 2905-12.
30. Hwang AL, Haynes K, Hwang W-T et al. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013; 42: 1054-9.
31. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 2007; 213: 589-602.
32. Nakamura K, Sasajima J, Mizukami Y et al. Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One 2010; 5: e8824.
33. Yue W, Yang CS, Di Paola RS et al. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila. PA) 2014; 7: 388-97.
34. Inoki K, Ouyang H, Zhu T et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-68.
35. Fryer LGD, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-32.
36. Kisfalvi K, Eibl G, Sinnett-Smith J et al. Metformin disrupts crosstalk between G Protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539-45.
37. Park JW, Jang J-Y, Kim E-J et al. Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg 2013; 100: 1064-70.
38. Muniraj T, Chari S. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol 2012; 58: 331-45.
39. Curtis LH, Hammill BG, Eisenstein EL et al. Using inverse probabilityweighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45: S103-7.
40. Grymonpre R, Cheang M, Fraser M et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44: 471-7.
41. Antwi SO, Oberg AL, Shivappa N et al. Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. Carcinogenesis 2016; 37: 481-90.
42. Müller MW, Friess H, Köninger J et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 2008; 195: 221-8.
43. Park JK, Yoon YB, Kim Y-T et al. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 2008; 42: 86-91.